Patents Examined by Bruce D. Hissong
  • Methods for identifying allosteric modulators of ship polypeptides
    Patent number: 8956824
    Abstract: This invention provides a method for identifying allosteric modulators of a SHIP polypeptide, wherein said SHIP polypeptide is contacted with a test compound, and wherein said SHIP polypeptide comprises an allosteric site selected from the group consisting of a SHIP C2 domain and a SHIP PH domain.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: February 17, 2015
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Alice Mui, Christopher Ong, Gerald Krystal, Raymond Andersen
  • Biphasic lipid-vesicle compositions
    Patent number: 8945529
    Abstract: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 3, 2015
    Assignee: Helix BioPharma Corporation
    Inventors: Marianna Foldvari, Praveen Kumar, John M. Docherty
  • CD127 binding proteins
    Patent number: 8940303
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: January 27, 2015
    Assignee: Glaxo Group Limited
    Inventors: Ian Kirby, Alex H. Taylor, Thomas Matthew Webb, Yu Xue
  • Compositions comprising modified biologically active polypeptides
    Patent number: 8933197
    Abstract: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: January 13, 2015
    Assignee: Amunix Operating Inc.
    Inventors: Willem P. Stemmer, Volker Schellenberger
  • Stable liquid interferon beta formulations
    Patent number: 8932574
    Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: January 13, 2015
    Assignee: Biogen Idec MA Inc.
    Inventors: Mary D. DiBiase, Wen-Li Chung, Mark Staples, Eric Scharin
  • Immunotherapeutic method involving CD123 (IL-3R?) antibodies and immunostimulating complex
    Patent number: 8920803
    Abstract: A method for the treatment of a condition which is characterized by CD 123-expressing cells in a patient comprises administering to the patient (i) an antibody or antibody fragment which binds selectively to IL-3R?(CD 123), and (ii) an immunostimulating complex which comprises saponin, a sterol and a phospholipid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: December 30, 2014
    Assignee: CSL Limited
    Inventors: Debra Pauline Drane, Eugene Maraskovsky, Jefferey Stephen Boyle
  • Diagnostic oral device
    Patent number: 8920340
    Abstract: Described herein are devices and methods for identifying the existence of an oral condition in a subject.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: December 30, 2014
    Assignee: Colgate-Palmolive Company
    Inventors: Elizabeth Gittins, Harsh M. Trivedi, Sharon Kennedy, Madhusudan Patel
  • Antibody fusion proteins with a modified FcRn binding site
    Patent number: 8907066
    Abstract: Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Kin-Ming Lo, Pascal A. Stein
  • Compositions and methods for increasing serum half-life
    Patent number: 8883982
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 11, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar, Erik Vogan
  • Protein formulations and methods of making same
    Patent number: 8883146
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Inc.
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Methods for treatment of cardiovascular disease
    Patent number: 8871452
    Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: October 28, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Richard T. Lee
  • Methods of treatment using human antibodies that bind IL-12
    Patent number: 8865174
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 21, 2014
    Assignee: AbbVie Inc.
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Kantor, John Gawain Elvin, Alexander Robert Duncan, Elaine J. Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Method for identifying immune response modulators
    Patent number: 8846308
    Abstract: Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate interaction of IL-2 promoter with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Method of treating individuals who have or are suspected of having autoimmune disease, inflammatory disease, cell, tissue or organ transplantation, or coronary artery disease, and methods of treating individuals who have or are suspected of having infectious disease, cancer, or who are immunocompromised or undergoing vaccination are disclosed.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 30, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Bin Li
  • Methods of decreasing glycosylated hemoglobin in patients with dyslipidemia
    Patent number: 8846758
    Abstract: Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1? modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1? modulator.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 30, 2014
    Assignee: TWi Biotechnology, Inc.
    Inventors: Mannching Sherry Ku, Chih-Kuang Chen, Wei-Shu Lu, Chih-Ming Chen, I-Yin Lin
  • Anti-MRP3 antibodies and methods of use
    Patent number: 8835608
    Abstract: An antibody having an antigen binding region capable of binding an epitope located in an extracellular portion of MRP3 and methods of utilizing same are provided. In particular, the invention provides antibodies targeted at a MRP3 antigen present on cells expressing MRP3 and methods useful in detecting or targeting cells expression the MRP3 antigen, as well as kits, nucleic acids, polypeptides, and cells for providing the antibodies.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: September 16, 2014
    Assignee: Duke University
    Inventors: Chien-Tsun Kuan, Darell D Bigner
  • Methods for treating Friedreich's ataxia with interferon gamma
    Patent number: 8815230
    Abstract: Described herein are compositions and methods for treating Friedreich's Ataxia (FRDA) with interferon gamma. In some aspects, methods for increasing expression of frataxin in cells and for treating Friedreich's Ataxia are provided. In some additional aspects, methods increasing aconitase activity in cells are provided.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: August 26, 2014
    Inventors: Roberto Testi, Barbara Tomassini
  • Peptides for inhibiting chemokine binding to chemokine receptors
    Patent number: 8796227
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: August 5, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • Methods of identifying NF-?B inhibitors
    Patent number: 8790883
    Abstract: The present invention relates to polypeptides that inhibit the NF-?B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: July 29, 2014
    Assignee: Institut Pasteur
    Inventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Vernon, Francois Traincard, Shoji Yamaoka
  • Maspin-based peptides and methods of use thereof
    Patent number: 8791233
    Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: July 29, 2014
    Assignee: Northwestern University
    Inventor: Ming Zhang
  • Human antibodies that bind human interleukin-12
    Patent number: 8765918
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: July 1, 2014
    Assignee: Abbott GmbH & Co., KG
    Inventors: Jochen G. Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Edward Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou